Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- pitolisant
- tripelennamine
Interactions between your drugs
tripelennamine pitolisant
Applies to: tripelennamine, pitolisant
GENERALLY AVOID: Because pitolisant enhances the activity of histaminergic neurons in the brain, centrally acting histamine H1-receptor antagonists or medicines with H1-receptor antagonist properties (e.g., tri- and tetracyclic antidepressants) may impair the efficacy of pitolisant.
MANAGEMENT: According to the manufacturer, coadministration of pitolisant with centrally acting H1-receptor antagonists or tri- and tetracyclic antidepressants should be avoided.
References (2)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2019) "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC
Drug and food interactions
tripelennamine food
Applies to: tripelennamine
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Lumryz
Lumryz (sodium oxybate) is used for the treatment of patients with narcolepsy. Includes Lumryz side ...
Xywav
Xywav is used for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Sunosi
Sunosi (solriamfetol) is a prescription medicine used for the treatment of excessive sleepiness in ...
Adderall
Adderall (amphetamine and dextroamphetamine) is used to treat narcolepsy and ADHD. Includes side ...
Concerta
Concerta is used to treat attention deficit disorder (ADD) and attention deficit hyperactivity ...
Ritalin
Ritalin (methylphenidate) is used to treat attention deficit disorder (ADD) and narcolepsy ...
Provigil
Provigil promotes wakefulness and is used to treat excessive daytime sleepiness caused by ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.